Editas Medicine (EDIT)

• Market cap: $419M
• 1 day: 3.02%
• 5 days: 5.41%
• 1 month: -25.21%
• 3 months: -9%
• 6 months: 40%
• Year to date: 33.17%
• 1 year: 6.64%
• 5 years: -94.07%
• 10 years: -89.08%
• Sector: Healthcare
• Industry: Biotechnology

About: Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Employees: 87